Exelixis, Inc. (NASDAQ:EXEL) insider Patrick J. Haley sold 20,000 shares of Exelixis stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $17.32, for a total value of $346,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Exelixis stock traded down $0.45 on Friday, reaching $16.67. The company had a trading volume of 4,233,603 shares, compared to its average volume of 4,612,580. The stock has a market cap of $5.18 billion, a price-to-earnings ratio of 32.69, a price-to-earnings-growth ratio of 1.03 and a beta of 2.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.54 and a current ratio of 8.66. Exelixis, Inc. has a 1 year low of $13.42 and a 1 year high of $32.20.
Exelixis (NASDAQ:EXEL) last announced its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.22. The firm had revenue of $225.40 million during the quarter, compared to analysts’ expectations of $174.14 million. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The company’s quarterly revenue was up 47.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 EPS. Sell-side analysts predict that Exelixis, Inc. will post 1.3 earnings per share for the current fiscal year.
A number of research firms have issued reports on EXEL. BidaskClub raised Exelixis from a “strong sell” rating to a “sell” rating in a research note on Tuesday. Piper Jaffray Companies reduced their price objective on Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday, November 5th. Oppenheimer set a $40.00 price objective on Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 1st. Guggenheim assumed coverage on Exelixis in a report on Monday, September 17th. They issued a “buy” rating for the company. Finally, Goldman Sachs Group assumed coverage on Exelixis in a report on Monday, September 17th. They issued a “neutral” rating and a $22.00 target price for the company. Three analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Exelixis has a consensus rating of “Buy” and a consensus price target of $29.44.
TRADEMARK VIOLATION WARNING: “Exelixis, Inc. (EXEL) Insider Patrick J. Haley Sells 20,000 Shares of Stock” was first reported by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.wkrb13.com/2018/11/10/exelixis-inc-exel-insider-patrick-j-haley-sells-20000-shares-of-stock.html.
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More: Hedge Funds
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.